179 related articles for article (PubMed ID: 28434293)
1. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Perlini S; Merlini G
Amyloid; 2017 Mar; 24(sup1):54-55. PubMed ID: 28434293
[No Abstract] [Full Text] [Related]
2. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.
Muchtar E; Dispenzieri A; Leung N; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves W; Kourelis TV; Warsame R; Russell SJ; Lust JA; Lin Y; Go RS; Zeldenrust SR; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Leukemia; 2019 Feb; 33(2):527-531. PubMed ID: 30258095
[No Abstract] [Full Text] [Related]
3. Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis.
Abeykoon JP; Paludo J; Dispenzieri A; Gertz MA; Dingli D; Baudi FK; Gonsalves WI; Kyle RA; Lacy MQ; Hayman SR; Leung N; Kourelis T; Rajkumar SV; Kumar S; Kapoor P
Amyloid; 2017 Mar; 24(sup1):50-51. PubMed ID: 28434368
[No Abstract] [Full Text] [Related]
4. Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.
Godara A; Toskic D; Albanese J; Rosenthal B; Siddiqui NS; Kugelmass A; Zhou P; Fogaren T; Varga C; Landau HJ; Comenzo RL
Am J Hematol; 2021 Jan; 96(1):E20-E23. PubMed ID: 33068021
[No Abstract] [Full Text] [Related]
5. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type.
Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar VS; Gertz MA
Amyloid; 2017 Mar; 24(sup1):44-45. PubMed ID: 28434304
[No Abstract] [Full Text] [Related]
6. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
Saith SE; Maurer MS; Patel AR
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
8. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
10. Revisiting complete response in light chain amyloidosis.
Sidana S; Dispenzieri A; Murray DL; Go RS; Buadi FK; Lacy MQ; Gonsalves WI; Dingli D; Warsame R; Kourelis T; Muchtar E; Hayman SR; Kapoor P; Kyle RA; Leung N; Rajkumar SV; Gertz MA; Kumar SK
Leukemia; 2020 May; 34(5):1472-1475. PubMed ID: 31772296
[No Abstract] [Full Text] [Related]
11. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
12. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
13. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
Wong SW; Fogaren T
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
[TBL] [Abstract][Full Text] [Related]
14. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.
Cohen OC; Law S; Lachmann HJ; Sharpley F; Ravichandran S; Mahmood S; Sachchithanantham S; Whelan CJ; De Azcona Naharro AM; Fontana M; Hawkins PN; Gillmore JD; Wechalekar AD
Blood Cancer J; 2020 May; 10(5):60. PubMed ID: 32444621
[No Abstract] [Full Text] [Related]
15. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Lavatelli F; Nuvolone M; Ferraro G; Palladini G; Merlini G
Amyloid; 2017 Mar; 24(sup1):64-65. PubMed ID: 28434343
[No Abstract] [Full Text] [Related]
16. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
17. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
18. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
[TBL] [Abstract][Full Text] [Related]
19. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.
Kumar SK; Gertz MA; Dispenzieri A
J Clin Oncol; 2019 Jan; 37(2):171-173. PubMed ID: 30433848
[No Abstract] [Full Text] [Related]
20. Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids.
Campbell P; Murdock C
Intern Med J; 2006 Feb; 36(2):137-9. PubMed ID: 16472271
[No Abstract] [Full Text] [Related]
[Next] [New Search]
